Chemical modification of recombinant human granulocyte colony-stimulating factor by polyethylene glycol increases its biological activity in vivo.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Cell Structure and Function

• Publication date

  1992-06-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1247/CSF.17.157PMID 1379521
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats.

  1991cited by this paper
• Pharmacokinetics and pharmacodynamics of recombinant human granulocyte-colony stimulating factor after intravenous and subcutaneous administration in the rat.

  1989cited by this paper
• Altered Properties ofSerratiaSuperoxide Dismutase by Chemical Modification

  1988cited by this paper
• Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers.

  1988cited by this paper
• Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model.

  1987cited by this paper
• Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells.

  1986cited by this paper
• Inducible production of human macrophage growth factor, CSF-1.

  1986cited by this paper
• The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors.

  1986cited by this paper
• Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor

  1986cited by this paper
• Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor.

  1985cited by this paper
• Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates.

  1984cited by this paper
• Enhanced responsiveness of committed macrophage precursors to macrophage-type colony-stimulating factor (CSF-1) induced in vitro by interferons alpha + beta 1.

  1983cited by this paper
• New developments in isoelectric focusing.

  1980cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper

• Discovery of proteolytically stable monocyte locomotion inhibitory factor peptide through systematic structural optimization.

  2025cites this paper
• Effect of Modification Strategies on the Biological Activity of Peptides/Proteins

  2023cites this paper
• Synthesis of gamma radiation-induced PEGylated cisplatin for cancer treatment

  2018cites this paper
• Inte rfe ro ne s pe gilado s : re vis ió n pre liminar de s us caracte rís ticas farmaco ciné ticas

  2016cites this paper
• Reagents for the Covalent Attachment of mPEG to Peptides and Proteins

  2015cites this paper
• Novel reactive PEG for amino group conjugation

  2015cites this paper
• Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor

  2015cites this paper
• Fully Synthetic Granulocyte Colony-Stimulating Factor Enabled by Isonitrile-Mediated Coupling of Large, Side-Chain-Unprotected Peptides.

  2015cites this paper
• Evolution of Reactive mPEG Polymers for the Conjugation of Peptides and Proteins

  2013cites this paper
• In vivo pharmacokinetics and pharmacodynamics of positional isomers of mono-PEGylated recombinant human granulocyte colony stimulating factor in rats.

  2013cites this paper
• PEGylation of lysine residues reduces the pro-migratory activity of IGF-I.

  2013cites this paper
• Comparação farmacocinética de duas formulações de alfapeginterferona em voluntários sadios

  2012cites this paper
• GEMMA and MALDI-TOF MS of reactive PEGs for pharmaceutical applications.

  2010cites this paper
• Old friends in new constellations--the hematopoetic growth factors G-CSF, GM-CSF, and EPO for the treatment of neurological diseases.

  2008cites this paper
• Cellular Encapsulation Techniques: Camouflaging Islet Cells from the Immune and Inflammatory Responses Associated with Islet Transplantation

  2008cites this paper
• Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs.

  2006cites this paper
• Conjugation of Multiple Copies of Polyethylene Glycol to Hemoglobin Facilitated Through Thiolation: Influence on Hemoglobin Structure and Function

  2005cites this paper
• Carbohydrate-specifically polyethylene glycol-modified ricin A-chain with improved therapeutic potential.

  2005cites this paper
• Influence of the chemistry of conjugation of poly(ethylene glycol) to Hb on the oxygen-binding and solution properties of the PEG-Hb conjugate.

  2005cites this paper
• Enteral Bioavailability of Human Granulocyte Colony Stimulating Factor Conjugated with Poly(ethylene glycol)

  2004cites this paper
• Pegylation of Interferon Alfa: Structural and Pharmacokinetic Properties

  2003cites this paper
• Structure, biology, and therapeutic implications of pegylated interferon alpha-2b.

  2002cites this paper
• Pegfilgrastim

  2002cites this paper
• La pegilación de fármacos

  2002cites this paper
• Características farmacológicas de los interferones pegilados

  2002cites this paper
• [Pegylated interferons: preliminary review of their pharmacokinetic characteristics].

  2001cites this paper
• Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

  2001cites this paper
• Interferones pegilados: revisión preliminar de sus características farmacocinéticas

  2001cites this paper
• Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation.

  2000cites this paper
• Improving on Nature by Re-Engineering Hematopoietic Growth Factors

  1999cites this paper
• Polyethylene glycol-conjugated pharmaceutical proteins

  1998cites this paper
• Effect of divalent polyethylene glycol units, conjugated on human granulocyte colony-stimulating factor, on biological activities in vitro and in vivo.

  1998cites this paper
• In Vivo Effects of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor on Hematopoiesis in Normal Mice

  1996cites this paper
• Characterization and Stability of N-terminally PEGylated rhG-CSF

  1996cites this paper
• Pharmacological effects of recombinant human granulocyte colony-stimulating factor modified by polyethylene glycol on anticancer drug-induced neutropenia in mice.

  1994cites this paper
• Pulmonary absorption of polyethylene glycolated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF)

  1994cites this paper
• Protein tailoring of human granulocyte colony-stimulating factor

  1993cites this paper